摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-bis(tert-butyl)-4-hydroxyphenylpropionic acid | 13917-37-8

中文名称
——
中文别名
——
英文名称
3,5-bis(tert-butyl)-4-hydroxyphenylpropionic acid
英文别名
2-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoic acid;3,5-di-tert-butyl-4-hydroxyphenylpropionic acid;2-(3,5-di-tert-butyl-4-hydroxyphenyl)propionic acid;4-hydroxy-3,5-di-t-butyl-phenyl-propionic acid;4-hydroxy-3,5-di-tert-butylphenyl propionic acid;3,5-di-t-butyl-4-hydroxyphenylpropionic acid;2-(3,5-ditert-butyl-4-hydroxyphenyl)propanoic acid
3,5-bis(tert-butyl)-4-hydroxyphenylpropionic acid化学式
CAS
13917-37-8
化学式
C17H26O3
mdl
——
分子量
278.392
InChiKey
FANGQVKSFHFPBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    200-201 °C
  • 沸点:
    344.1±37.0 °C(Predicted)
  • 密度:
    1.046±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,5-bis(tert-butyl)-4-hydroxyphenylpropionic acid对甲苯磺酸苯甲醇 作用下, 以 甲苯 为溶剂, 生成 4-hydroxy-3,5-di-t.-butylphenyl-propionic acid benzyl ester
    参考文献:
    名称:
    4-Hydroxy-3,5-di-alkyl-phenyl-propionic acid composition suitable as
    摘要:
    作用于代谢的制药组合物,包含作为活性衍生物的4-羟基-3,5-二烷基苯丙酸,其对应于公式I和II,其中R1和R2可以相同也可以不同,分别代表具有1至8个碳原子的烷基基团,R3代表具有2至12个碳原子的烷基基团,X代表羟基,具有1至18个碳原子的烷氧基,具有1至4个烷基碳原子的苯基烷氧基,具有5至8个碳原子的环烷氧基,-NR4R5中,R4代表具有1至18个碳原子的烷基团,R5代表氢原子或R4和R5可以与氮原子形成一个杂环六元环,该六元环可以携带另一个杂原子,n是从2到4的整数。以及其制备方法。
    公开号:
    US03969530A1
  • 作为产物:
    参考文献:
    名称:
    4-Hydroxy-3,5-di-alkyl-phenyl-propionic acid composition suitable as
    摘要:
    作用于代谢的制药组合物,包含作为活性衍生物的4-羟基-3,5-二烷基苯丙酸,其对应于公式I和II,其中R1和R2可以相同也可以不同,分别代表具有1至8个碳原子的烷基基团,R3代表具有2至12个碳原子的烷基基团,X代表羟基,具有1至18个碳原子的烷氧基,具有1至4个烷基碳原子的苯基烷氧基,具有5至8个碳原子的环烷氧基,-NR4R5中,R4代表具有1至18个碳原子的烷基团,R5代表氢原子或R4和R5可以与氮原子形成一个杂环六元环,该六元环可以携带另一个杂原子,n是从2到4的整数。以及其制备方法。
    公开号:
    US03969530A1
  • 作为试剂:
    描述:
    3,5-bis(tert-butyl)-4-hydroxyphenylpropionic acid氧气 作用下, 以 为溶剂, 生成 苯酚
    参考文献:
    名称:
    Skuratova, S. I.; Ostapets, G. D., Russian Journal of Physical Chemistry, 1983, vol. 57, # 11, p. 1755 - 1756
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
    申请人:——
    公开号:US20030078420A1
    公开(公告)日:2003-04-24
    The invention relates to new derivatives of 2-(iminomethyl)amino-phenyl which are NO synthase inhibitors and can trap reactive oxygen species. These compounds can notably be used for the treatment of stroke, of neurodegenerative diseases and of ischemic or hemorragic cardiac or cerebral infarctions. These compounds include: N-{4-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-{3-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-(4-{[{[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}(methyl)amino]methyl}phenyl)thiophene-2-carboximidamide; N-[3-({[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-(3-{[(3,5-di-tert-butyl-4-hydroxybenzyl)amino]methyl}phenyl) thiophene-2-carboximidamide; N-[3-({[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-[3-({[3-(4-hydroxy-3,5-diisopropylphenyl)propyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-(3-{[(4-hydroxy-3,5-diisopropylbenzyl)amino]methyl}phenyl) thiophene-2-carboximidamide; N-[3-({[2-(4-hydroxy-3,5-diisopropylphenyl)ethyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-2-(3,5-di-tert-butyl-4-hydroxybenzoyl)-N-1-(4-{[imino(thien-2-yl)methyl]amino}phenyl)-L-leucinamide; and pharmaceutically acceptable salts thereof.
    这项发明涉及新的2-(亚甲基亚胺)氨基苯基衍生物,它们是一氧化氮合酶抑制剂,可以捕获活性氧物质。这些化合物可以显著用于中风、神经退行性疾病、缺血性或出血性心脏或脑梗死的治疗。 这些化合物包括: N-4-[(4-(3,5-二叔丁基-4-羟基苯基)-1,3-噻唑-2-基}甲基)氨基]苯基}噻吩-2-甲酰亚胺; N-3-[(4-(3,5-二叔丁基-4-羟基苯基)-1,3-噻唑-2-基}甲基)氨基]苯基}噻吩-2-甲酰亚胺; N-(4-[4-(3,5-二叔丁基-4-羟基苯基)-1,3-噻唑-2-基}甲基(甲基)氨基]甲基}苯基)噻吩-2-甲酰亚胺; N-[3-([3-(3,5-二叔丁基-4-羟基苯基)丙基]氨基}甲基)苯基]噻吩-2-甲酰亚胺; N-(3-[(3,5-二叔丁基-4-羟基苯基)甲基]氨基}苯基)噻吩-2-甲酰亚胺; N-[3-([2-(3,5-二叔丁基-4-羟基苯基)乙基]氨基}甲基)苯基]噻吩-2-甲酰亚胺; N-[3-([3-(4-羟基-3,5-二异丙基苯基)丙基]氨基}甲基)苯基]噻吩-2-甲酰亚胺; N-(3-[(4-羟基-3,5-二异丙基苯基)甲基]氨基}苯基)噻吩-2-甲酰亚胺; N-[3-([2-(4-羟基-3,5-二异丙基苯基)乙基]氨基}甲基)苯基]噻吩-2-甲酰亚胺; N-2-(3,5-二叔丁基-4-羟基苯甲酰)-N-1-4-[imino(噻唑-2-基)甲基]氨基}苯基-L-亮氨酰; 及其药学上可接受的盐。
  • [EN] NOVEL COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS ET LEURS UTILISATIONS
    申请人:NANYANG POLYTECHNIC
    公开号:WO2010144055A1
    公开(公告)日:2010-12-16
    The invention relates to compounds represented by the general formula (I): and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group; with the proviso that when n = 2, R1 is not -OCH3 on the carbon-3 position of the phenyl group and R1 is not -OH on the carbon-4 position of the phenyl group.
    该发明涉及由通式(I)表示的化合物及其药学上可接受的盐,其中n是1到5的整数;p是0到4的整数;R1从羟基、烷氧基、硫醇基和硫醚基组成的群体中选取;R2和R3独立地是亚甲基基团或亲核试剂,但至少其中之一是亲核试剂基团;Z是氧(O)原子或硫(S)原子;T是氢或可选择取代的脂肪族基团;但当n=2时,R1不是苯基的碳-3位置上的-甲氧基,且R1不是苯基的碳-4位置上的-羟基。
  • STABILIZATION OF HOUSEHOLD, BODY-CARE AND FOOD PRODUCTS BY USING BENZOTROPOLONE CONTAINING PLANT EXTRACTS AND/OR RELATED BENZOTROPOLONE DERIVATIVES
    申请人:Wagner Barbara
    公开号:US20120230925A1
    公开(公告)日:2012-09-13
    Disclosed is the use of benzotropolone derivatives of formula (1), wherein R 1 , R 2 and R 7 independently from each other are hydrogen; C 1 -C 3 alkyl; or COR 8 ; R 3 is hydrogen; or COOR 9 R 4 is hydrogen; or C 1 -C 3 alkyl; R 5 is hydrogen; hydroxy; C 1 -C 3 -alkoxy; or -0-(CO)—R 10 ; R 6 is hydrogen; C 1 -C 3 alkyl; or COR 8 ; or R 5 and R 6 together may form a five or six membered ring; or R 6 and R 7 together form a five or six membered ring; and R 8 , R 9 , R 10 independently of each other are C 1 -C 30 alkyl; for protecting body-care and household products from photolytic and oxidative degradation.
    本发明涉及一种使用化学式(1)中的苯并三酮衍生物的方法,其中R1、R2和R7分别独立地为氢原子;C1-C3烷基;或COR8;R3为氢原子;或COOR9;R4为氢原子;或C1-C3烷基;R5为氢原子;羟基;C1-C3-烷氧基;或-0-(CO)—R10;R6为氢原子;C1-C3烷基;或COR8;或R5和R6可以共同形成五元或六元环;或R6和R7可以共同形成五元或六元环;且R8、R9、R10分别独立地为C1-C30烷基;用于保护身体护理和家用产品免受光解和氧化降解的方法。
  • High purity monoalkyltin compounds and uses thereof
    申请人:ARKEMA FRANCE
    公开号:EP2123659A1
    公开(公告)日:2009-11-25
    The present invention relates to high purity monoalkyltin compounds, more specifically to alkyltin compound compositions containing monoalkyltin as major compound, and minor quantities of di- and/or trialkyltin compounds. The present invention also relates to the preparation processes of such high purity monoalkyltin compounds, as well as to the uses of said monoalkyltin compounds as chlorine-containing polymer-stabilisers, glass coating chemicals and catalysts, as well as articles comprising at least one polymer matrix and a high purity monoalkyltin compound.
    本发明涉及高纯度的单烷基锡化合物,更具体地是含有单烷基锡作为主要化合物的烷基锡化合物组合物,以及少量的二烷基锡和/或三烷基锡化合物。本发明还涉及制备这种高纯度单烷基锡化合物的过程,以及将所述单烷基锡化合物用作含氯聚合物稳定剂、玻璃涂层化学品和催化剂的用途,以及包含至少一个聚合物基质和高纯度单烷基锡化合物的制品。
  • COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS
    申请人:Mousa Shaker A.
    公开号:US20110105482A1
    公开(公告)日:2011-05-05
    A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ 3 integrin antagonist in the same molecule.
    一种双重甲状腺整合素拮抗剂及其治疗介导血管生成障碍和/或甲状腺功能亢进症的方法,通过将双重甲状腺整合素拮抗剂引入动物(例如哺乳动物、人类)来实现。双重甲状腺整合素拮抗剂包括一种具有甲状腺激素拮抗剂和αvβ3整合素拮抗剂的化学结构在同一分子中。
查看更多